Montelukast Unimark (Montelukast Sodium)

Montelukast acts as a selective antagonist of the cysteinyl leukotriene receptor CysLT1. By blocking this receptor, it prevents leukotrienes from causing bronchoconstriction, airway edema, mucus production and inflammatory cell recruitment, thereby improving breathing and reducing allergic symptoms.

The dose of Montelukast Unimark is determined by the prescribing clinician based on the patient’s age, indication and clinical response. The prescriber will select the appropriate strength and dosing schedule that best fits the individual’s therapeutic needs.

Safety data for Montelukast in pregnancy are limited, and it is classified as a category where benefits must outweigh potential risks. During breastfeeding, only limited information is available; clinicians should assess the risk‑benefit ratio before continuing therapy.

To place an order, submit an enquiry on the Montelukast Unimark product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who prefer oral therapy or have aspirin‑exacerbated respiratory disease, but it may be less potent than high‑dose inhaled steroids for severe asthma control.

Montelukast Unimark should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Montelukast Unimark is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, and the dosing time (morning or evening) should follow the prescriber’s instructions to maintain consistent plasma levels.

Serious adverse events include severe allergic reactions such as rash or angioedema, neuropsychiatric effects like depression or suicidal thoughts, and rare hepatic or skin disorders such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these symptoms develop.

Montelukast Unimark is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Caution is also advised for patients with a history of severe psychiatric disorders, liver disease, or those taking interacting medications without proper monitoring.